PT2694116T - Nanopartículas à base de lípidos - Google Patents

Nanopartículas à base de lípidos

Info

Publication number
PT2694116T
PT2694116T PT12767275T PT12767275T PT2694116T PT 2694116 T PT2694116 T PT 2694116T PT 12767275 T PT12767275 T PT 12767275T PT 12767275 T PT12767275 T PT 12767275T PT 2694116 T PT2694116 T PT 2694116T
Authority
PT
Portugal
Prior art keywords
lipid
based nanoparticles
nanoparticles
Prior art date
Application number
PT12767275T
Other languages
English (en)
Portuguese (pt)
Inventor
Annapragada Ananth
L Eriksen Jason
A Tanifum Eric
Dasgupta Indrani
c cook Stephen
Original Assignee
Univ Texas
Alzeca Biosciences Llc
Board Of Regents Of The Univ Of Houston System
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2694116(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Alzeca Biosciences Llc, Board Of Regents Of The Univ Of Houston System, Texas Childrens Hospital filed Critical Univ Texas
Publication of PT2694116T publication Critical patent/PT2694116T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT12767275T 2011-04-06 2012-04-06 Nanopartículas à base de lípidos PT2694116T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06

Publications (1)

Publication Number Publication Date
PT2694116T true PT2694116T (pt) 2018-10-12

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12767275T PT2694116T (pt) 2011-04-06 2012-04-06 Nanopartículas à base de lípidos

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP3366313A1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR101973063B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6212032B2 (ja) 2011-04-06 2017-10-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 脂質ベースのナノ粒子
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3542828A1 (en) * 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
PT3458074T (pt) * 2016-05-16 2024-08-21 Univ Texas Composições para a entrega de trna na forma de nanopartículas e métodos de utilização com os mesmos
CN110022859B (zh) 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
EP3914230A4 (en) * 2019-01-24 2023-06-07 Alzeca Biosciences, Llc <SMALLCAPS/>? ? ?FUNCTIONALIZED LIPOSOMES FOR IMAGE MISFOLDED PROTEINS
CN115916263B (zh) * 2020-01-29 2025-10-03 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
US20210252170A1 (en) 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
EP0752889B1 (en) 1994-03-28 2002-06-26 Nycomed Imaging AS Liposomes containing a x-ray- or ultrasound contrast agent
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
EP1233752B1 (en) * 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Radiation sensitive liposomes
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) * 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
EP2010223A2 (en) * 2006-04-07 2009-01-07 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
EP2217146A4 (en) 2007-12-05 2015-10-14 Marval Biosciences Inc NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
US20090311191A1 (en) 2008-06-13 2009-12-17 Ananth Annapragada Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US20120003159A1 (en) 2009-03-19 2012-01-05 Board Of Regents Of The University Of Texas System Compositions and methods for enhancing contrast in imaging
WO2010115080A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2012119117A1 (en) 2011-03-02 2012-09-07 Sensulin, Llc Vesicle compositions
JP6212032B2 (ja) 2011-04-06 2017-10-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 脂質ベースのナノ粒子
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
EP2694116A4 (en) 2015-06-03
US9801957B2 (en) 2017-10-31
CA2831480C (en) 2020-09-29
KR20140074868A (ko) 2014-06-18
AU2012239888B9 (en) 2017-10-12
AU2017232156A1 (en) 2017-10-12
AU2019246775A1 (en) 2019-10-31
US20120258044A1 (en) 2012-10-11
KR101973063B1 (ko) 2019-04-30
EP2694116A2 (en) 2014-02-12
ES2685824T3 (es) 2018-10-11
CN104144708A (zh) 2014-11-12
JP6533813B2 (ja) 2019-06-19
KR102035187B1 (ko) 2019-11-08
MX357227B (es) 2018-07-02
EP3366313A1 (en) 2018-08-29
BR112013025633A2 (pt) 2017-08-08
CA2831480A1 (en) 2012-10-11
CN104144708B (zh) 2017-07-28
DK2694116T3 (en) 2018-09-03
JP2014523854A (ja) 2014-09-18
PL2694116T3 (pl) 2018-12-31
AU2012239888B2 (en) 2017-06-22
AU2017232156B2 (en) 2019-07-11
MX2013011231A (es) 2015-03-05
AU2012239888A1 (en) 2013-11-07
KR20190031334A (ko) 2019-03-25
JP2019151664A (ja) 2019-09-12
WO2012139080A2 (en) 2012-10-11
JP2018035167A (ja) 2018-03-08
AU2017232156C1 (en) 2019-10-24
HK1203827A1 (en) 2015-11-06
AU2012239888A2 (en) 2014-05-08
WO2012139080A3 (en) 2014-05-01
JP6212032B2 (ja) 2017-10-18
EP2694116B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
DK3424953T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
EP2755962A4 (en) AZAINDAZOLES
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
EP2662268A4 (en) CAP MOUNTING STRUCTURE
EP2776444A4 (en) dihydropteridinones
PL2694116T3 (pl) Nanocząstki na bazie lipidów
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2695208A4 (en) MICRO-THERMOCOUPLE
DK2770906T3 (en) Applanationstonometer
GB201103926D0 (en) Lock-alarm
SG11201402471SA (en) Photocatalyst-supporting structure
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU5026P (en) Goldstrike Agapanthus inapertus
AU5171P (en) Sunparamiho Mandevilla xamabilis
GB201102529D0 (en) Fine B-Day
GB201109229D0 (en) New uses
AP00723S1 (en) Autorickshaw
AU338110S (en) Barstool
GB201102013D0 (en) Aimspray easyreach
AU339857S (en) Orchidometer
AU338420S (en) Kettlebell
GB201100008D0 (en) Jigsawing